P1.059. Calcium-Channel Blocker Use and Survival After Neoadjuvant Therapy for Locally Advanced ESCC

Clicks: 15
ID: 326086
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #425 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Calcium-channel blockers (CCBs) are commonly prescribed for cardiovascular disease. Beyond hemodynamic effects, experimental studies suggest that CCBs may modulate tumor biology through interference with apoptosis and alterations in proliferative signaling, however, clinical evidence remains inconsistent and may depend on tumor histology and treatment modality.Whether CCB exposure influences outcomes in esophageal squamous cell carcinoma (ESCC) treated with neoadjuvant therapy followed by radical esophagectomy is unclear. We investigated the association between CCB use and survival outcomes in this study. Methods We retrospectively analyzed a prospectively maintained cohort of patients with locally advanced ESCC treated with neoadjuvant chemotherapy (nCT) or chemoradiotherapy (nCRT) followed by curative-intent esophagectomy. Primary endpoints were overall survival (OS) and disease-free survival (DFS). Survival was estimated using Kaplan–Meier curves and evaluated using multivariable Cox proportional hazards models, with prespecified subgroup analyses by neoadjuvant regimen A causal mediation analysis decomposed the association between CCB use and OS into direct effects and indirect effects. Results Among 580 patients, 56 (9.6%) used CCBs, 275 (47.4%) received nCT and 305 (52.6%) received nCRT. Neoadjuvant regimen type was not associated with OS (p=0.745) or DFS (p=0.358). Baseline characteristics were reported as well balanced between CCB users and non-users. Overall, CCB use was associated with worse OS (HR=1.50; p=0.084) and DFS (HR=1.49; p=0.057). In subgroup analysis, CCB use was linked to inferior outcomes after nCRT (OS: HR=1.90; p=0.024; DFS: HR=1.80; p=0.026), with no clear association after nCT. Mediation analysis suggested predominantly indirect effects via DFS in the overall cohort (HR=1.50; p<0.001) and nCRT subgroup (HR=1.90; p<0.001). Conclusion CCB use was associated with inferior survival in ESCC patients receiving neoadjuvant chemoradiotherapy, with mediation analyses suggesting this association operates largely through higher recurrence risk. No consistent association was observed after neoadjuvant chemotherapy. These findings are hypothesis-generating and support prospective validation, treatment-interaction assessment, and mechanistic studies, including evaluation of perioperative factors and complications that could confound or modify the observed associations.
Reference Key
openalex_W7203982254 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Su Feng, Subinuer Maimaiti, Xu Huang, Jun Yin, Yaxing Shen
Are you one of these authors? Claim your profile
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.207
URL
https://doi.org/10.1093/dote/doag077.207
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.